fda semaglutide compounding enforcement october 2025 Diabetes advocacy group discourages use of compounded GLP-1 drugs FDA issued 25 warning letters

This should remove any remaining baking soda residue as well as the fish odor

A class of drugs known as GLP-1 receptor agonists (GLP-1 RAs) have recently garnered significant attention for their potential to promote substantial weight loss

The confusion surrounding this topic often stems from individual patient experiences and the multifactorial nature of testosterone regulation

Since the first such case was filed in 2023, at least 4,400 patients have filed lawsuits that are now part of consolidated federal and state litigation, numbers that are expected to grow as part of legal challenges expected to take several years

GLP-1 class medications carry a known cautionary flag here